Xeris Biopharma Holdings, Inc.
XERS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867096
In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 11 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Xeris Biopharma Holdings, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 201 | 2 | 231 | +32 |
| Shares | 90.6M | 580.2K | 97.0M | +6.99M (+7.8%) |
| Value | $422.9M | $2.71M | $789.3M | +$369.1M (+87.8%) |
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (59)
Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (27)
Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (2)
Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 561,700 | $2.62M |
| CIBC World Markets Corp | 18,473 | $86.3K |